Updated analyses from clinical trials evaluating Adcetris in combination with Opdivo (nivolumab), as well as encore analyses from the phase 3 ECHELON-1, ECHELON-2 and ALCANZA clinical trials, will be highlighted in 12 presentations at EHA and ICML.
Adcetris is an antibody-drug conjugate directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas.
Opdivo is a programmed death-1 immune checkpoint inhibitor that is designed to harness the body's own immune system to help restore anti-tumor immune response.
Adcetris and Opdivo are not approved in combination for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma, HL, pediatric HL or for other indications. Adcetris in combination with bendamustine is not approved for HL.
Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercialises transformative therapies targeting cancer to make a meaningful difference in people's lives.
Adcetris (brentuximab vedotin) utilizes the company's industry-leading antibody-drug conjugate technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.
Beyond Adcetris, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors.
Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology.
Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer.
In addition, it is leveraging expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.
The company is headquartered in Bothell, Washington, and has a European office in Switzerland.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886